The global hospital acquired disease testing market has increasing morbidity rates worldwide due to infections, along with the prevalence of pathogens, bacterial, fungal & viral diseases, among its vital growth drivers. Another important driving force is increasing length of stay in the hospital which is primarily due to hospital-acquired infections. HAI is more likely to occur in the intensive care units (ICU) & the emergency rooms (ER). CDC, U.S. estimates that 5% of patients admitted in a hospital get HAI of any form within 72 hours of their stay. Infections incubating but clinically not visible at the time of admission are excluded. The most frequent type of infection that spreads in hospital settings are bacterial nosocomial infections. These infections are commonly transmitted when hospital staff do not practice proper hygiene correctly & become complacent.
Globally, the Hospital acquired disease testing market is categorized based on infection types into the following segments: bloodstream infection (BSI) testing, urinary tract infection (UTI) testing, methicilin-resistant staphylococcus aureus (MRSA) testing, pneumonia testing, surgical site infection (SSI) testing & other infections such as cardio vascular infection, gastrointestinal infections & respiratory infections. Of all the different types of Nosocomial infection, urinary tract infection is the most common one & has the largest share in the overall HAI testing market. The popular techniques that are being used for preventing, diagnosing & treating the hospital-associated infections are PCR, solid-phase hybridization, microarrays. There are different government bodies, which provide defined guidelines for the control & prevention of HAI in developing countries. National health & medical research council, Australia & CDC, U.S. have provided a framework of recommendations to healthcare organizations to manage the different types of HAI.
North America has the largest share in the hospital acquired disease testing market followed by Europe. Due to the increase in the medical tourism industry in Asian countries, the Asia-Pacific market is expected to flourish in the forecasted period. The key players in this market include - Life technologies, Diatherix laboratories, Qiagen GmbH, Meridian Biosciences, Nordion, Roche, Cantel Medical Corporation, Cepheid & others.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.